<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177643</url>
  </required_header>
  <id_info>
    <org_study_id>07943212.5.2002.0053</org_study_id>
    <secondary_id>CAAE: 07943212.5.2002.0053</secondary_id>
    <nct_id>NCT02177643</nct_id>
  </id_info>
  <brief_title>Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin</brief_title>
  <official_title>Effect of Diacerein in the Metabolic Control of Patients With Diabetes Mellitus Type 2 and Secondary Failure to Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANS Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Considering that, Diacerein is on the market for almost 20 years, being used continuously in
      elderly patients with osteoarthritis without present significant side effects, and
      considering the anti-hyperglycemic effect and the improvement in the insulin resistance
      observed in animal models of type 2 diabetes and in a previously study from Mexico. The aim
      of our study is to investigate the effect of Diacerein, a medication with anti-osteoarthritic
      properties and moderately analgesic activity, anti-inflammatory and antipyretic, which
      demonstrates inhibit properties for the synthesis of pro-inflammatory cytokines such as
      interleukin 1 (IL-1). Administered for 12 weeks and the effect in the glycemic and metabolic
      control in patients with diabetes mellitus 2 and secondary failure to metformin treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proof of concept study aims to access the metabolic control in patients with type 2
      diabetes mellitus and secondary failure to metformin.

      The Study is a Phase II, Multicenter, National, Prospective, Randomized, Double blind,
      Parallel Groups, Placebo Comparative Trial. UNICAMP (Hospital of Unicamp) is the coordinating
      center and we have the participation of the State University of Feira de Santana and the
      Center for Diabetes and Hypertension in Fortaleza.

      Study Objectives: To investigate the effect of Diacerein administered for 12 weeks; glycemic
      and metabolic control in patients with diabetes mellitus 2 and secondary failure to metformin
      treatment. The Total Number of patients will be approximately 60, 30 patients in each group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Glucose Concentration</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Insulin Concentration</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1c - glycated haemoglobin</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Activity Profile</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>TNFα IL6 IL1β C-Reactive Protein (CRP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid Panel</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Function Panel</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes-Related Complications</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Diacerein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remains of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diacerein</intervention_name>
    <description>Diacerein oral capsules</description>
    <arm_group_label>Diacerein</arm_group_label>
    <other_name>Artrodar - TRB Pharma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus (DM) type 2 between 6 months to 10 years of disease

          -  Body mass index between 25 and 35 kg/m2

          -  Fasting glucose between 120 and 250 mg/dL

          -  Glycated Hb A1c greater than 7,5 %

          -  Taking Metformin (dose above 1700 mg/day) with or without other secretagogue.

        Exclusion Criteria:

          -  Subjects with DM1

          -  Subjects with DM2 using insulin

          -  Subjects with DM2 with chronic complications that already have clinical consequences

          -  Subjects with other types of diabetes

          -  Creatinine serum greater than 1.4 mg/dl (female) and 1.5 mg/dl (male)

          -  History of heart disease and/or severe concomitant diseases such as liver, coronary
             artery, renal

          -  History of severe psychiatric or neurological disorders

          -  History of alcohol abuse and/or illegal drugs or psychotropic medicines in the past
             six months

          -  Hypersensitivity to any component of the of study drug and placebo formulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Mario JA Saad, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Science and Technology of Obesity and Diabetes (CNPq)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dra. Maria Cândida R. Parisi, PhD</last_name>
    <phone>+55 (019) 981962242</phone>
    <email>emaildacandida@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aleksandra A. Silva, MSc</last_name>
    <phone>+55 (019) 99233-9701</phone>
    <email>aleksandra.silva@anspharma.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Estadual de Feira de Santana</name>
      <address>
        <city>Feira de Santana</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dra. Ana Mayra A. Oliveira, PhD</last_name>
      <phone>+55 (075) 3625-4027</phone>
      <email>anamayra@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Dra. Ana Mayra A. Oliveira, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos em Diabetes e Hipertensão</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dra. Adriana C. Forti, PhD</last_name>
      <phone>+55 (085) 3105-8300</phone>
      <email>cedh@cedh.med.br</email>
    </contact>
    <investigator>
      <last_name>Dra. Adriana C. Forti, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dra. Maria Cândida R. Parisi, PhD</last_name>
      <phone>+55 (019) 98196-2242</phone>
      <email>emaildacandida@uol.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Daniel Minuti, MD Msc</last_name>
      <phone>+55 (019) 98128-2535</phone>
      <email>danielminutti@yahoo.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Dr. Daniel Minuti, MD Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://press.endocrine.org/doi/abs/10.1210/en.2011-0249</url>
    <description>Diacerhein Improves Glucose Tolerance and Insulin Sensitivity in Mice on a High-Fat Diet</description>
  </link>
  <reference>
    <citation>Ramos-Zavala MG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, González-López R, Santiago-Hernández NJ. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care. 2011 Jul;34(7):1591-4. doi: 10.2337/dc11-0357. Epub 2011 May 24.</citation>
    <PMID>21610123</PMID>
  </reference>
  <reference>
    <citation>Tobar N, Oliveira AG, Guadagnini D, Bagarolli RA, Rocha GZ, Araujo TG, Prada PO, Saad MJ. Comment on: Ramos-Zavala et al. Effect of diacerein on insulin secretion and metabolic control in drug-naïve patients with type 2 diabetes: a randomized clinical trial. Diabetes Care 2011;34:1591-1594. Diabetes Care. 2012 Feb;35(2):e13; author reply e14. doi: 10.2337/dc11-1856.</citation>
    <PMID>22275450</PMID>
  </reference>
  <reference>
    <citation>Tobar N, Oliveira AG, Guadagnini D, Bagarolli RA, Rocha GZ, Araújo TG, Santos-Silva JC, Zollner RL, Boechat LH, Carvalheira JB, Prada PO, Saad MJ. Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet. Endocrinology. 2011 Nov;152(11):4080-93. doi: 10.1210/en.2011-0249. Epub 2011 Sep 6.</citation>
    <PMID>21896669</PMID>
  </reference>
  <reference>
    <citation>Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk between the insulin and angiotensin II signaling systems. Diabetes Metab Res Rev. 2006 Mar-Apr;22(2):98-107. Review.</citation>
    <PMID>16389635</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>September 15, 2015</last_update_submitted>
  <last_update_submitted_qc>September 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Aleksandra Alves Silva</investigator_full_name>
    <investigator_title>Study Director - Dr. Mario José Abdalla Saad - National Institute of Science and Technology of Obesity and Diabetes</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diacerein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Diacetylrhein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

